Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues - PubMed (original) (raw)
. 1987 Jan 15;47(2):414-8.
- PMID: 3539322
Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues
B C Behrens et al. Cancer Res. 1987.
Abstract
Human ovarian cancer cell lines with stable cisplatin resistance have been developed by chronic exposure of the parent cisplatin-sensitive A2780 line to increasing concentrations of cisplatin. 2780CP8 (CP8 refers to this cell line's growth in medium containing 8 microM cisplatin) has several clonal cytogenetic abnormalities but lacks homogeneously staining regions or double-minute chromosomes. It has a significantly greater monolayer growth rate, cloning efficiency in agarose, and total glutathione content compared to the A2780 line, but similar activities of several glutathione-dependent enzymes. The 2780CP8 subline is 7.3-fold resistant to cisplatin compared to the A2780 line, as well as cross-resistant to irradiation and melphalan. It is not cross-resistant to Adriamycin, but this develops with increased cisplatin resistance (14-fold) obtained by further cisplatin exposure of 2780CP8. Of the cisplatin analogues tested which are of current clinical interest, carboplatin, iproplatin, and tetraplatin, only the latter is more cytotoxic than cisplatin in the A2780 and 2780CP8 lines. The 2780CP8 subline is also cross-resistant to these analogues in the relative order carboplatin greater than iproplatin greater than tetraplatin (most to least cross-resistant). Treatment of a highly cisplatin resistant cell line (2780CP70) with either melphalan or cisplatin was associated with a significant increase in [3H]thymidine incorporation into DNA in the presence of 10 mM hydroxyurea compared with the parent sensitive cell line which showed essentially no capacity to repair DNA damage by these drugs. A2780 and its cisplatin-resistant cell lines may thus be useful in studying drug resistance mechanisms, in screening new drugs for activity (especially against drug resistant tumors), and in formulating induction and salvage therapies for ovarian cancer.
Similar articles
- Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line.
Kelland LR, Mistry P, Abel G, Freidlos F, Loh SY, Roberts JJ, Harrap KR. Kelland LR, et al. Cancer Res. 1992 Apr 1;52(7):1710-6. Cancer Res. 1992. PMID: 1312897 - Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W, Chaney SG. Schmidt W, et al. Cancer Res. 1993 Feb 15;53(4):799-805. Cancer Res. 1993. PMID: 8428361 - Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II).
Teicher BA, Holden SA, Kelley MJ, Shea TC, Cucchi CA, Rosowsky A, Henner WD, Frei E 3rd. Teicher BA, et al. Cancer Res. 1987 Jan 15;47(2):388-93. Cancer Res. 1987. PMID: 3539321 - [The mechanism of cisplatin-resistance in ovarian cancer].
Kikuchi Y. Kikuchi Y. Hum Cell. 2001 Jun;14(2):115-33. Hum Cell. 2001. PMID: 11552292 Review. Japanese. - New platinum agents. A comparison in ovarian cancer.
Kelland LR, McKeage MJ. Kelland LR, et al. Drugs Aging. 1994 Aug;5(2):85-95. doi: 10.2165/00002512-199405020-00002. Drugs Aging. 1994. PMID: 7981487 Review.
Cited by
- New anti-ovarian cancer quinolone derivatives acting by modulating microRNA processing machinery.
Felicetti T, Di Iacovo N, Della Fazia MA, Piobbico D, Pieroni S, Pacetti M, Yu J, Sun Y, Massari S, Barreca ML, Sabatini S, Tabarrini O, Cecchetti V, Wang F, Pommier Y, Morlando M, Servillo G, Manfroni G. Felicetti T, et al. RSC Med Chem. 2024 Sep 27. doi: 10.1039/d4md00649f. Online ahead of print. RSC Med Chem. 2024. PMID: 39399313 Free PMC article. - Mitochondrial and Cytosolic One-Carbon Metabolism Is a Targetable Metabolic Vulnerability in Cisplatin-Resistant Ovarian Cancer.
Wallace-Povirk A, O'Connor C, Dekhne AS, Bao X, Nayeen MJ, Schneider M, Katinas JM, Wong-Roushar J, Kim S, Polin L, Li J, Back JB, Dann CE 3rd, Gangjee A, Hou Z, Matherly LH. Wallace-Povirk A, et al. Mol Cancer Ther. 2024 Jun 4;23(6):809-822. doi: 10.1158/1535-7163.MCT-23-0550. Mol Cancer Ther. 2024. PMID: 38377173 - DNA Double-Strand Break Repair Inhibitors: YU238259, A12B4C3 and DDRI-18 Overcome the Cisplatin Resistance in Human Ovarian Cancer Cells, but Not under Hypoxia Conditions.
Macieja A, Gulbas I, Popławski T. Macieja A, et al. Curr Issues Mol Biol. 2023 Sep 28;45(10):7915-7932. doi: 10.3390/cimb45100500. Curr Issues Mol Biol. 2023. PMID: 37886943 Free PMC article. - Expression of Ferredoxin1 in cisplatin‑resistant ovarian cancer cells confers their resistance against ferroptosis induced by cisplatin.
Takahashi R, Kamizaki K, Yamanaka K, Terai Y, Minami Y. Takahashi R, et al. Oncol Rep. 2023 Jun;49(6):124. doi: 10.3892/or.2023.8561. Epub 2023 May 5. Oncol Rep. 2023. PMID: 37144519 Free PMC article. - Comparative analysis of chlorambucil-induced DNA lesion formation and repair in a spectrum of different human cell systems.
Krassnig SC, Mäser M, Probst NA, Werner J, Schlett C, Schumann N, von Scheven G, Mangerich A, Bürkle A. Krassnig SC, et al. Toxicol Rep. 2023 Jan 20;10:171-189. doi: 10.1016/j.toxrep.2023.01.010. eCollection 2023. Toxicol Rep. 2023. PMID: 36714466 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials